AWM Investment Company Inc. Acquires New Shares in TriSalus Life Sciences, Inc. $TLSI

AWM Investment Company Inc. bought a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,250,000 shares of the company’s stock, valued at approximately $6,812,000. AWM Investment Company Inc. owned 3.30% of TriSalus Life Sciences as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Nantahala Capital Management LLC purchased a new position in shares of TriSalus Life Sciences during the second quarter valued at approximately $10,900,000. Geode Capital Management LLC grew its position in TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after purchasing an additional 235,627 shares during the period. Goldman Sachs Group Inc. purchased a new stake in TriSalus Life Sciences during the 1st quarter valued at $187,000. Connective Capital Management LLC raised its stake in TriSalus Life Sciences by 12.8% during the 2nd quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after buying an additional 3,717 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at $108,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Down 2.7%

NASDAQ:TLSI opened at $7.30 on Friday. The business’s 50-day simple moving average is $5.31 and its two-hundred day simple moving average is $5.02. TriSalus Life Sciences, Inc. has a 52 week low of $3.42 and a 52 week high of $7.70. The stock has a market cap of $364.71 million, a PE ratio of -3.61 and a beta of 0.43.

TriSalus Life Sciences (NASDAQ:TLSI) last released its earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The company had revenue of $11.57 million during the quarter, compared to analysts’ expectations of $11.76 million. Sell-side analysts anticipate that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 1st. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.50.

TriSalus Life Sciences Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.